Dermatology

This site is intended for healthcare professionals only

Login Register

MD Brand Connect
Vaccine Hub
MDTV
Fact Check
Health Dialogues

Medical News & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry
MDTV

This site is intended for healthcare professionals only

Login Register

LoginRegister

Home
Medical news & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry

Farhat Nasim

Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Home

Farhat Nasim

Articles By : Farhat Nasim

Glenmark Favipiravir can be used in mild Covid cases, says doctor; Check out Consent Form

Farhat Nasim22 Jun 2020 12:20 PM IST

Meanwhile, Glenmark has released a consent form. A copy of which is with Medical Dialogues. Entailing responsible medication use, the form should be...

DoP junks Skymap Pharma review plea against NPPA for Fluconazole Tablets

Farhat Nasim22 Jun 2020 11:35 AM IST

New Delhi: In a major setback to Skymap Pharmaceuticals Limited, the Department of Pharmaceuticals (DoP) has rejected the review application filed by...

Shilpa Medicare to acquire FTF Pharma for Rs 75 crore, pick up 40pc stake in Auxilla Pharma for Rs 60 crore

Farhat Nasim18 Jun 2020 7:18 PM IST

New Delhi: Shilpa Medicare Ltd, recently said that it is all set to acquire FTF Pharma Private Limited while it will also pick up a 40% stake in...

Aarogya Setu App: Govt suspends website promoting e-pharmacies post HC order

Farhat Nasim18 Jun 2020 3:26 PM IST

The plea has said the website is linked to the Aarogya Setu app in a highly illegal, arbitrary, and discriminatory manner.

Drug samples including cough-cold syrup fails quality test, declared Not Of Standard Quality

Farhat Nasim17 Jun 2020 6:09 PM IST

New Delhi: The apex drug regulatory body, Central Drugs Standard Control Organization (CDSCO) flagged 59 drug samples that failed to qualify a random...

Unfortunate: Mumbai doctor succumbs to COVID-19

Farhat Nasim17 Jun 2020 9:15 AM IST

Mumbai: In an unfortunate incident, a senior female doctor attached with civic-run Chatrapati Shivaji Maharaj Hospital in Kalwa succumbed to...

Defective COVID Test Kits: Licence for Chinese kits issued only after validation, DCGI tells court

Farhat Nasim16 Jun 2020 4:52 PM IST

The court was further informed via a counter affidavit by the Indian Council of Medical Research (ICMR) that clarified that the kits of Guangzhou...

18 Medical Device Firms Got Rs 133.95 Cr in Incentives Till FY2024-25: Govt Tells RS

DoP presents draft guidelines for Rs 6500-crore pharma incentive scheme; Details

Farhat Nasim15 Jun 2020 6:04 PM IST

New Delhi: Through a recent notification, the Department of Pharmaceuticals(DoP) has rolled out draft guidelines for the Rs 6,940 crore...

Delhi HC restrains firm from using trademark similar to Sun Pharma BP drug Labebet

Farhat Nasim14 Jun 2020 12:45 PM IST

New Delhi: In a major relief to drug giant, Sun Pharmaceuticals Laboratories Limited, the Delhi High Court has recently restrained BDR Pharmaceuticals...

Combating COVID-19: India to soon begin domestic production of Remdesivir drug

Farhat Nasim14 Jun 2020 10:15 AM IST

"Pharma companies have been directed to conduct Active-Post Marketing Surveillance of each case and prepare a report on the benefit or recovery of a...

Sun Pharma presents Clinical Insights of ODOMZO, LEVULAN KERASTICK for Treating People With Risk of Skin Cancer

Farhat Nasim14 Jun 2020 10:15 AM IST

Mumbai: Sun Pharmaceutical Industries Ltd. recently announced that one of its wholly-owned subsidiaries presented data analyses for two of its...

Sun Pharma announces insights into clinical use of ILUMYA in moderate-to-severe plaque psoriasis

Farhat Nasim13 Jun 2020 11:54 AM IST

Furthermore, the safety profile of ILUMYA was reconfirmed in a five-year analysis that demonstrated low and similar exposure-adjusted incidence rates...

Powered By: Hocalwire

X

We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok